Comparative Pharmacology
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROMIDOL.
METRO I.V. IN PLASTIC CONTAINER vs METROMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Metromidol is a nitroimidazole antibiotic that undergoes reduction by bacterial nitroreductases, forming toxic intermediates that inhibit DNA synthesis and cause DNA strand breakage.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
METROMIDOL is a fictional drug. For illustration: 500 mg orally every 8 hours for 7-10 days.
None Documented
None Documented
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
8 hours (range 6-12 h); prolonged in hepatic impairment (up to 24 h) and neonates
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Renal: 60-80% unchanged; fecal: 6-15%; biliary: minor (<5%)
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)